Evogene Ltd.

1.18+0.0122+1.04%Vol 85.52K1Y Perf -57.99%
Aug 16th, 2022 16:00 DELAYED
BID1.12 ASK1.21
Open1.18 Previous Close1.17
Pre-Market- After-Market1.25
 - -  0.07 5.93%
Target Price
8.67 
Analyst Rating
Strong Buy 1.00
Potential %
634.75 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.78
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     51.01
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
17.24 
Earnings Rating
Strong Sell
Market Cap48.60M 
Earnings Date
31st Aug 2022
Alpha-0.02 Standard Deviation0.23
Beta1.36 

Today's Price Range

1.151.20

52W Range

0.68003.58

5 Year PE Ratio Range

-3.50-3.20

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
12.38%
1 Month
45.68%
3 Months
29.37%
6 Months
-4.07%
1 Year
-57.99%
3 Years
-23.87%
5 Years
-75.11%
10 Years
-72.56%

TickerPriceChg.Chg.%
EVGN1.180.01221.04
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
21.00
-3 827.80
-3 545.40
-1 891.80
-
RevenueValueIndustryS&P 500US Markets
699.00K
0.02
-22.23
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.14-0.20-42.86
Q04 2021-0.20-0.1810.00
Q03 2021-0.17-0.19-11.76
Q02 2021--0.15-
Q01 2021--0.17-
Q04 2020--0.25-
Q03 2020--0.17-
Q02 2020--0.16-
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.18-12.50Negative
9/2022 QR-0.20-11.11Negative
12/2022 FY-0.72-2.86Negative
12/2023 FY-0.4425.42Positive
Next Report Date31st Aug 2022
Estimated EPS Next Report-0.18
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume85.52K
Shares Outstanding41.19K
Shares Float39.71M
Trades Count288
Dollar Volume100.35K
Avg. Volume124.82K
Avg. Weekly Volume127.69K
Avg. Monthly Volume126.39K
Avg. Quarterly Volume120.37K

Evogene Ltd. (NASDAQ: EVGN) stock closed at 1.18 per share at the end of the most recent trading day (a 1.04% change compared to the prior day closing price) with a volume of 85.52K shares and market capitalization of 48.60M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 139 people. Evogene Ltd. CEO is Ofer Haviv.

The one-year performance of Evogene Ltd. stock is -57.99%, while year-to-date (YTD) performance is -28.05%. EVGN stock has a five-year performance of -75.11%. Its 52-week range is between 0.68 and 3.58, which gives EVGN stock a 52-week price range ratio of 17.24%

Evogene Ltd. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.91, a price-to-sale (PS) ratio of 68.81, a price to cashflow ratio of 81.70, a PEG ratio of 2.32, a ROA of -36.91%, a ROC of -48.12% and a ROE of -50.34%. The company’s profit margin is -%, its EBITDA margin is -3 545.40%, and its revenue ttm is $699.00 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Evogene Ltd., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. Evogene Ltd.’s next earnings report date is 31st Aug 2022.

The consensus rating of Wall Street analysts for Evogene Ltd. is Strong Buy (1), with a target price of $8.67, which is +634.75% compared to the current price. The earnings rating for Evogene Ltd. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evogene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evogene Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.97, ATR14 : 0.12, CCI20 : 140.89, Chaikin Money Flow : 0.09, MACD : 0.07, Money Flow Index : 66.82, ROC : 46.01, RSI : 61.17, STOCH (14,3) : 93.03, STOCH RSI : 1.00, UO : 59.12, Williams %R : -6.97), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evogene Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Evogene Ltd.

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

CEO: Ofer Haviv

Telephone: +972 89311900

Address: 13 Gad Feinstein Street, Rehovot 7612002, , IL

Number of employees: 139

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

67%33%


News

Stocktwits